Abstract
The early detection of skin cancer is of critical importance, as it can lead to in fatal outcomes if left unaddressed. Given the limited accessibility of dermatological expertise to the general population, it becomes imperative to devise an economical, efficacious, and precise methodology capable of efficient&reliable diagnosis of melanoma and other forms of skin cancer. A data-driven paradigm emerges as the optimal solution for the early and accurate identification of skin malignancies. In this study, we explored an array of Machine Learning (ML) and Deep Learning (DL) algorithms, identifying the most effective model for this context.To conduct this study, we utilized the ISIC 2024 challenge dataset, which contains images of cropped skin lesions, along with metadata associated with each lesion.The developed algorithm is operable without the necessity for specialized clinical intervention and demonstrates exceptional accuracy in differentiating between malignant and benign skin cancer cases, utilizing both cropped skin lesion images from Total Body Photography (TBP) and corresponding tabular data/metadata. For CSV format metadata, Random Forest performed best with an accuracy of 99.928% and an F1-Score of 99.92%, and for cropped skin lesion images, ConViT Tiny performed best with an accuracy of 96.99% and an F1-Score of 96.9%. The output of the proposed work would help in creating a benchmark for preliminary diagnosis of the cancerous tissues and timely prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Dataset is openly available at: ISIC 2024 challenge.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
nishantsharma.research{at}gmail.com
Data Availability
Dataset is openly available at: ISIC 2024 challenge.
